CytoMed Therapeutics GDTC
NASDAQ GDTC
$0.91 +0.04 (+4.42%)
As of: Oct 21, 2026 · 3:59 PM EDT

CytoMed Therapeutics (GDTC) Receivables - Other (2021 - 2026)

Updated

CytoMed Therapeutics (GDTC) recorded Receivables - Other of $375,976 in Q4 2025, unchanged from $375,888 a year earlier.

Analysis

CytoMed Therapeutics (GDTC) Receivables - Other (2021 - 2026) Analysis & Trends

At the end of FY2025, CytoMed Therapeutics reported Receivables - Other of $372,965, down 0.4% from FY2024.

  • Annual Receivables - Other has a five-year compound annual growth rate of 56.1% (FY2020 to FY2025).
  • Across earlier years, Receivables - Other came in at $374,305 in FY2024 (-66.0%), $1.1 million in FY2023 (+20.5%), $914,144 in FY2022 (+18.9%) and $768,975 in FY2021.
  • The Q4 2025 figure is the highest quarterly Receivables - Other since Q2 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,172.45 Bn 1,141.04 Bn 19.71 Bn
2 Johnson & Johnson 637.59 Bn 556.11 Bn 17.26 Bn
3 AbbVie 504.05 Bn 477.16 Bn 12.70 Bn
4 Merck 377.18 Bn 331.56 Bn 12.21 Bn
5 Novartis Ag 304.13 Bn 268.12 Bn 11.24 Bn
6 Astrazeneca 267.62 Bn 241.31 Bn 12.86 Bn
7 Amgen 241.83 Bn 197.23 Bn 7.24 Bn
8 Gilead Sciences 194.07 Bn 168.27 Bn 6.22 Bn
9 Pfizer 172.51 Bn 119.15 Bn 10.94 Bn
10 CytoMed Therapeutics 10.29 Mn 1.11 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 329,378.00
Dec 31, 2025 379,532.66
Jun 30, 2025 -182,122.00
Dec 31, 2024 367,844.52
Jun 30, 2024 1.24 Mn
Dec 31, 2023 196,332.78
Jun 30, 2023 1.03 Mn
Dec 31, 2022 108,884.12
Dec 31, 2021 15,180.01
API Access

CytoMed Therapeutics Receivables - Other API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-other&ticker=GDTC&period=max&api_key=YOUR_API_KEY